Plasma cell separation algorithm from bone marrow samples;Algoritmus separace plazmatických buněk ze vzorků kostní dřeně

Klinicka Onkologie

Volumn 24, Issue 1, 2011, Pages 35-40

  Buresova I ^a   Kyjovska D ^a,b   Kovarova L ^b   Moravcova J ^a   Suska R ^b   Perutka, T ^a   Cumova J ^a   Hájek, Roman ^a,b  

^a MASARYK UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Cell sorter; Magnetic separation; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Plasma cell separation

Indexed keywords

SYNDECAN 1;

ALGORITHM; ARTICLE; BONE MARROW CULTURE; CELL FRACTIONATION; CELL SEPARATION; CELL SORTER; CLINICAL ARTICLE; DENSITY GRADIENT CENTRIFUGATION; ERYTHROCYTE; FLOW CYTOMETRY; HEMOLYSIS; HOSPITAL PATIENT; HUMAN; HUMAN CELL; INFORMED CONSENT; LABELING INDEX; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OUTPATIENT; PLASMA CELL;

EID: 79952350354     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Fillola G, Muller C, Bousquet R et al. Isolation of bone marrow plasma cells by negative selection with immunomagnetic beads. J Immunol Methods 1996; 190(1): 127-131. (Pubitemid 26098906)
2. Tai YT, Teoh G, Shima Y et al. Isolation and characterization of human multiple myeloma cell enriched populations. J Immunol Methods 2000; 235(1-2): 11-19. (Pubitemid 30089779)
3. Avet-Loiseau H, Facon T, Daviet A et al. 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome. Cancer Res 1999; 59(18): 4546-4550. (Pubitemid 29428955)
4. Draube A, Pfister R, Vockerodt M et al. Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol 2001; 80(2): 83-89 (Pubitemid 32177953)
5. Davies FE, Dring AM, Li C et al. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003; 102(13): 4504-4511. (Pubitemid 37494117)
6. Rasillo A, Tabernero MD, Sánchez ML et al. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined dignificance versus multiple myeloma and plasma cell leukemia. Cancer 2003; 97(3): 601-609. (Pubitemid 36125837)
7. Fišerová S, Hájek R, Doubek M et al. Imunomagnetická separace myelomových buněk. Klin Onkol 2001; 14(2): 46-50.
8. Cumova J, Kovarova L, Potacova A et al. Optimalization of myeloma cell selection from bone marrow purified by magnetic-activated cell sorting. V přípravě.
9. Wijdenes J, Vooijs WC, Clément C et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol 1996; 94(2): 318-323. (Pubitemid 26247990)
10. Fonseca R, Barlogie B, Bataille R et al. Genetics and cytogenetics of multiple myeloma. A workshop report. Cancer Res 2004; 64(4): 1546-1558.
11. Witzig T, Kimlinger T, Stenson M et al Syndecan-1 expression on malignant cells from the blood and marrow of patients with plasma cell proliferative disorders and B-cell chronic lymphocytic leukemia. Leuk Lymphoma 1998; 31(1-2): 167-175. (Pubitemid 28428760)
12. Jourdan M, Ferlin M, Legouffe E et al The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998; 100(4): 637-646. (Pubitemid 28126093)
13. Paulus U, Dreger P, Viehmann K et al. Purging Peripheral Blood Progenitor Cell Grafts from lymphoma cells, quantitative comparison of immunomagnetic CD34+ selection systems. Stem Cells 1997; 15(4): 297-304. (Pubitemid 27315334)
14. Kuglík P, Filková H, Vranovà V et al. Detection of chromosome 13 abnormalities and 14q32 translocations in multiple myeloma using simultaneous immunofluorescent labelling of malignant plasma cells and FISH. Europ J Hum Genet 2004; 12 (Suppl): 170.
15. Ross FM, Avet-Loiseau H, Drach J et al. European myeloma network recommendations for FISH in myeloma (Abstract). Haematologica 2007; 92 (Suppl 2) 100-101.
16. Zhan F, Huang Y, Colla S et al. The molecular classification of multiple myeloma Blood 2006; 108(6): 2020-2028.
17. Shaughnessy JD Jr, Zhan F, Burington BE et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109(6): 2276-2284. (Pubitemid 46425864)
18. Decaux O, Lodé L, Magrangeas F et al. Intergroupe Francophone du Myélome. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. J Clin Oncol 2008; 26(29): 4798-4805.
19. Ansorgová V, Mačingová Z, Priester P et al. Nádorové kmenové buňky a "niche" - jako limitující faktor karcinogeneze Klin Onkol 2009; 22(1): 11-16.
20. Huff CA, Matsui W Multiple myeloma cancer stem cells J Clin Oncol 2008; 26(17): 2895-2900.